Intelligence · Clinical pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
Pipeline programs
-
000434
Ferring Pharmaceuticals
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours
1 trial -
115747
Disc Medicine
Metastatic renal cell carcinoma
1 trial -
131I-apamistamab
Actinium Pharmaceuticals
Acute Leukemia
1 trial -
1403-0008
Boehringer Ingelheim
Advanced dedifferentiated liposarcoma
1 trial -
1403-0019
Boehringer Ingelheim
dedifferentiated liposarcoma
1 trial -
1407-GUCG
Ningbo Cancer Hospital
Progressive or recurrent germ cell tumor (measurable or non-measurable)
1 trial -
1414-ROG-GUCG
Ningbo Cancer Hospital
very high risk localized or locally advanced prostate cancer
1 trial -
1438-0011
Boehringer Ingelheim
advanced or metastatic extrapulmonary neuroendocrine carcinoma
1 trial -
1438-0012
Boehringer Ingelheim
small cell lung cancer
1 trial -
14395
Disc Medicine
ABC borderline resectable pancreatic cancer
1 trial -
1479-0008
Boehringer Ingelheim
non-squamous non-small cell lung cancer
1 trial -
1479-0032
Boehringer Ingelheim
Non-small cell lung cancer
1 trial -
17000139BLC3001
Janssen-Cilag International N.V.
Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
1 trial -
17000139BLC3002
Janssen-Cilag International N.V.
High-Risk Non-muscle-invasive Bladder Cancer
1 trial -
17000139BLC3004
Janssen-Cilag International N.V.
High-Risk Non-muscle-invasive Bladder Cancer
1 trial -
177Lu-TLX591
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial -
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
2008-46
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
20170770
Amgen
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
1 trial -
20190009
Amgen
Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation
1 trial -
20190172
Amgen
Colorectal Cancer (CRC)
1 trial -
20190360
Amgen
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults
1 trial -
20200041
Amgen
Extensive stage small cell lung cancer (ES-SCLC)
1 trial -
2020HXFH037
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
2021/3336
The George Institute
Maintenance treatment in metastatic non-squamous lung cancer
1 trial -
20210081
Amgen
Colorectal Cancer (CRC)
1 trial -
20210096
Amgen
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression
1 trial -
20210098
Amgen
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
1 trial -
2022-009
Ningbo Cancer Hospital
metastatic breast cancer
1 trial -
2023/3764
The George Institute
Metastatic renal cell carcinoma (mRCC)
1 trial -
20230005
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
20230016
Amgen
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
1 trial -
20230127
Amgen
Early-stage Non-squamous Non-small Cell Lung Cancer
1 trial -
20230239
Amgen
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
20240178
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
213350/3000-03-005
TESARO Bio Netherlands B.V.
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
1 trial -
213400
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
213410
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
213823
GlaxoSmithKline
Lung Cancer, Non-Small Cell
1 trial -
2215-CL-0201
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
221530
GlaxoSmithKline
Neoplasms, Head and Neck
1 trial -
223674
GlaxoSmithKline
Neoplasms, Lung
1 trial -
22615
Bayer AG
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
1 trial -
3-dimensional conformal radiation therapy
United Therapeutics Europe Ltd
Head and Neck Cancer
1 trial -
4010-03-001
TESARO Bio Netherlands B.V.
Recurrent or primary advanced (Stage III or IV) endometrial cancer
1 trial -
42756493BLC3001
Janssen-Cilag International N.V.
Advanced Urothelial Cancer
1 trial -
42756493BLC3004
Janssen-Cilag International N.V.
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
1 trial -
42756493BLC3005
Janssen-Cilag International N.V.
High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.